Effectiveness and Resistance to PSMA Targeted RadioLigand Therapy using 177 Lu-PSMA-617 - Jeremie Calais

February 4, 2019

Jeremie Calais discusses his PCF funded research on 177 Lu-PSMA-617 with respect to resistance patterns that develop to treatment along with primary resistance.  Drs. Calais and Ryan discuss patient and tumor characteristics for both those demonstrating effectiveness to therapy and those that develop resistance or have primary resistance.


Jeremie Calais, MD, MSc Assistant Professor at the Ahmanson Translational Imaging Division of the Department of Molecular and Medical Pharmacology UCLA Nuclear Medicine Department Los Angeles, CA

Charles J. Ryan, MD is the B.J. Kennedy Chair in Clinical Medical Oncology at the University of Minnesota and Director of the Division of Hematology, Oncology and Transplantation.